Remergent™ is formulated by AGI Dermatics, the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, a molecular biologist with a specialty in gene repair, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin.

AGI Dermatics has distinguished itself as the first commercial skincare lab to recognize that DNA damage suppresses the skin's immune function. The company was also the first to demonstrate that DNA repair can preserve and restore healthy skin. Each of these breakthroughs—based on DNA science—is now considered fundamental to the future of genetic dermatology and general skincare.

The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. Its liposome-delivery systems are the company's core technology and the platform for Remergent products and many of its pharmaceuticals.

Developed to fill critical voids in current skincare therapies, Remergent products activate self-healing, reverse skin cell dysfunction, and maximize results for long term gain through prevention, repair and restoration.